In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.

[1]  J. Granada,et al.  Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.

[2]  G. Nakazawa,et al.  Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus‐eluting stents , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  K. Alexander,et al.  Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative , 2006, Circulation.

[4]  A. Garg,et al.  Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. , 2006, JAMA.

[5]  S. Steinhubl,et al.  Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. , 2006, The Journal of invasive cardiology.

[6]  Qi Zhang,et al.  Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention. , 2006, Chinese medical journal.

[7]  K. Alexander,et al.  Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.

[8]  G. Stone,et al.  Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. , 2005, American heart journal.

[9]  J. Yee,et al.  Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. , 2005, Clinical nephrology.

[10]  David J Cohen,et al.  Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. , 2005, American heart journal.

[11]  James J. Gugger,et al.  Percutaneous Coronary Intervention–Related Bleeding Risk Factors in Current Practice , 2005, The Annals of pharmacotherapy.

[12]  E. Topol,et al.  The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. , 2005, American heart journal.

[13]  P. Serruys,et al.  Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. , 2005, The American journal of cardiology.

[14]  J. J. Griffin,et al.  Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction , 2003, Circulation.

[15]  R. Califf,et al.  Anticoagulation in acute cardiac care in patients with chronic kidney disease. , 2003, American heart journal.

[16]  M. Bell,et al.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.

[17]  David O. Williams,et al.  ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .

[18]  K A Eagle,et al.  ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coro , 2001, Journal of the American College of Cardiology.

[19]  A. Levin,et al.  Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  I. Palacios,et al.  Are Patients With Renal Failure Good Candidates for Percutaneous Coronary Revascularization in the New Device Era? , 2000, Circulation.

[21]  S. Hosoda,et al.  Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. , 1996, The Annals of thoracic surgery.

[22]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[23]  A. Schwartz,et al.  Selective Reduction of Serotonin Storage and ATP Release in Chronic Renal Failure Patient Platelets , 1990, American journal of hematology.

[24]  B. Rutherford,et al.  Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. , 1990, American heart journal.

[25]  B. Gersh.  Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents , 2006 .

[26]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  J. Ioannidis,et al.  Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. , 2003, Journal of the American College of Cardiology.

[28]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .